Closing the personalized medicine information gap: HER2 test documentation practice

American Journal of Managed Care

Volumn 19, Issue 1, 2013, Pages 17-26

  Ferrusi, Ilia L ^a,b   Earle, Craig C ^c   Trudeau, Maureen ^d,e   Leighl, Natasha B ^e,f   Pullenayegum, Eleanor ^b,g   Khong, Hoa ^h   Hoch, Jeffrey S ^i,j   Marshall, Deborah A ^a,b,k  

^a CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

^h Alberta Bone and Joint Health Institute   (Canada)

ⁱ Pharmacoeconomics Research Unit   (Canada)

^j UNIVERSITY OF TORONTO   (Canada)

^k UNIVERSITY OF CALGARY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER REGISTRY; CANCER STAGING; COHORT ANALYSIS; COMORBIDITY; DATA BASE; DIAGNOSTIC TEST; FEMALE; HER2 TEST; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84875192278     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Canadian Cancer Society's Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2011. Toronto, Canada: Canadian Cancer Society; 2011.
2. Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 2004;6(6):229-239. (Pubitemid 39440251)
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182. (Pubitemid 17231334)
4. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707- 712. (Pubitemid 19147683)
5. Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist. 2008;13(6):620-630. (Pubitemid 351904907)
6. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366-3373.
7. Hanna W, O'Malley FP, Barnes P, et al. Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer. Curr Oncol. 2007;14(4):149-153.
8. Wolff AC, Hammond ME, Schwartz JN, et al; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118-145. (Pubitemid 350003059)
9. Trudeau M, Madarnas Y, McCready D, Pritchard KI, Messersmith H; Breast Cancer Disease Site Group. The Role of Trastuzumab in Adjuvant and Neoadjuvant Therapy in Women With HER2/Neu-Overexpressing Breast Cancer: A Clinical Practice Guideline. Toronto: Cancer Care Ontario; May 12, 2006. Report 1-24.
10. Lidgren M, Jönsson B, Rehnberg C, Willking N, Bergh J. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol. 2008;19(3):487-495. (Pubitemid 351325669)
11. Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a costeffectiveness analysis. J C lin Oncol. 2004;22(5):854-863. (Pubitemid 41103597)
12. Dendukuri N, Khetani K, McIsaac M, Brophy J. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ. 2007;176(10):1429-1434. (Pubitemid 46762020)
13. Phillips KA, Liang SY, Van Bebber S; Canpers Research Group. Challenges to the translation of genomic information into clinical practice and health policy: utilization, preferences and economic value. Curr Opin Mol Ther. 2008;10(3):260-266. (Pubitemid 351799277)
14. Snow S, Rayson D, Barnes P, Kara T, Younis T. Does HER2/neu status affect adjuvant chemotherapy utilization? a population-based analysis. Poster presented at: ASCO 2008 Breast Cancer Symposium; September 5-8, 2008; Washington, DC.
15. Spencer D, Strasbourg D. McGuinty Government Improving Access to Cancer-Fighting Drugs: Herceptin, Navelbine, Taxotere to Be Funded by Province. Toronto, Canada: Ontario Ministry of Health and Long-Term Care. http://news.ontario.ca/archive/en/2005/07/22/McGuinty-governmentimproving- accessto-cancerfightingdrugs.html. Published 2005. Accessed December 5, 2012.
16. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. http://www.cancerstaging.org/products/pasteditions.html. 2002. Accessed December 4, 2012.
17. Gibson D, Richards H, Chapman A. The national ambulatory care reporting system: factors that affect the quality of its emergency data. Int J Inf Qual. 2008;2(2):97-114.
18. Richards J, Brown A, Homan C. The data quality study of the Canadian Discharge Abstract database. Statistics Canada International Symposium Series: Proceedings. http://www5.statcan. gc.ca/bsolc/olc-cel/olc-cel?catno=11-522- X20010016282&lang=eng. Published 2001. Accessed December 5, 2012.
19. Iron K, Zagorski B, Sykora K, Manuel D. Living and Dying in Ontario: An Opportunity for Improved Health Information. Toronto, Canada: Institute for Clinical Evaluative Science. http://www.ices.on. ca/webpage.cfm?site-id= 1&org-id=31&morg-id=0&gsec-id=0&item-id=4720. Published March 2008. Accessed December 5, 2012.
20. Murphy B, Zhang X, Dionne C. Revising Statistics Canada's Low Income Measure (LIM). Income Research Paper Series. Ottawa: Statistics Canada. Pages 1-31. http://www.statcan. gc.ca/pub/75f0002m/75f0002m2010004-eng.htm. Published 2010. Accessed December 5, 2012.
21. Wolfson MC, Evans JM; Organisation for Economic Co-operation and Development. Statistics Canada's Low Income Cut-Offs Methodological Concerns and Possibilities. Ottawa: Statistics Canada, Analytical Studies Branch; 1989.
22. Statistics Canada. Postal Code Conversion File (PCCF), Reference Guide. 92-153-G ed. Ottawa, Canada: Statistics Canada. http://www5.statcan. gc.ca/bsolc/olc-cel/olc-cel?catno=92-153-G&lang=eng. Published May 2011. Accessed December 5, 2012.
23. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139. (Pubitemid 41587600)
24. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted inhospital mortality. J Clin Epidemiol. 2004;57(12):1288-1294. (Pubitemid 40023149)
25. Quail JM, Lix LM, Osman BA, Teare GF. Comparing comorbidity measures for predicting mortality and hospitalization in three population-based cohorts. BMC Health Serv Res. 2011;11:146.
26. Lester SC, Bose S, Chen YY, et al; Members of the Cancer Committee, College of American Pathologists. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med. 2009;133(10):1515-1538.
27. Synoptex NLP [software]. Artificial Intelligence in Medicine. http://www.aim.on. ca/system-integration/. 2011. Accessed October 16, 2011.
28. Quan ML, Hodgson N, Schultz SE, et al. Surgery for breast cancer. In: Urbach DR, Simunovic M, Schultz SE, eds. Cancer Surgery in Ontario: ICES Atlas. Toronto, Canada: Institute for Clinical Evaluative Sciences; 2008.
29. Webster R, Palaniappan N, Abraham J, Bertelli G, Jasani B, Barrett-Lee P. HER2 testing, adjuvant trastuzumab use and results: our experience in South Wales. Clin Oncol (R Coll Radiol). 2010;22(10):894.
30. Goddard KA, Weinmann S, Richert-Boe K, Chen C, Bulkley J, Wax C. HER2 evaluation and its impact on breast cancer treatment decisions. Public Health Genomics. 2012;15(1):1-10.
31. O'Malley FP, Thomson T, Julian J, et al. HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab. Arch Pathol Lab Med 2008;132(1):61-65.
32. Haas JS, Phillips KA, Liang SY, et al. Genomic testing and therapies for breast cancer in clinical practice. J Oncol Pract. 2011;7(3) (suppl):e1s-e7s.
33. Cancer Care Ontario. Collaborative staging. Surgical Oncology Newsletter. 2009;4(1). https://www.cancercare.on. ca/SurgicalOncology-News/766-776.htm. Accessed December 5, 2012.
34. Peacock S. Economics, personalized health care and cancer control. Presented at: 2011 CAPT Annual Conference; April 17, 2011; Ottawa, Ontario, Canada.